

EDITORIAL

A Foreword from the Editor

Jean-Marie Boeynaems, MD, PhD

Professor at the Université Libre de Bruxelles

Editor-in-Chief of the Journal of Medicines Development Sciences

<http://dx.doi.org/10.18063/JMDS.2015.02.007>.

We are glad to publish the second issue of the *Journal of Medicines Development Sciences*. It illustrates three current trends in medicines development:

- The rising role of small biotech companies,
- The initiatives launched in many countries to boost clinical research,
- The importance of an adequate education and training of physicians and scientists involved in medicines development.

The article of Barbaras on HDL therapies illustrates how biologics and small molecules can be developed in parallel by a company to achieve the same therapeutic goal. The review of Ena *et al.* emphasizes the rising importance of cell therapies using stem cells for organ repair. The articles of Chee *et al.* and Rosenkranz *et al.* illustrate the numerous initiatives launched in different parts of the world to boost medicines development; Korea and Africa represent two very different examples that are worth underscoring. The article of Aperia *et al.* shows the added value of the biopharmaceutical industry involvement in the training of PhD students; it provides one answer to a paper entitled ‘How to build a better PhD’, which was recently published in *Nature*^[1]. Last but not least, the article of Brooksbank *et al.* emphasizes the importance of lifelong learning for scientists involved in medicines development.

References

1. Gould J, 2015, How to build a better PhD, *Nature*, vol.528, 22–25.

<http://dx.doi.org/10.1038/528022a>.